Impact of intraoperative opioid and adjunct analgesic use on renal cell carcinoma recurrence: role for onco-anaesthesia

Br J Anaesth. 2020 Nov;125(5):e402-e404. doi: 10.1016/j.bja.2020.06.036. Epub 2020 Jul 21.

¹ Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Department of Surgery, University of Melbourne, Austin Hospital, Melbourne, Australia.
² Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
³ Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
⁴ Department of Anesthesiology, Weill Cornell Medicine, New York, NY, USA.
⁵ Department of Anesthesiology, Weill Cornell Medicine, New York, NY, USA; Department of Anesthesiology and Critical Care Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
⁶ Department of Anesthesiology, Weill Cornell Medicine, New York, NY, USA; Department of Anesthesiology and Critical Care Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA. Electronic address: mincerj@mskcc.org.

No abstract available

Keywords: analgesia; cancer; nephrectomy; oncological outcomes; opioids; renal cell carcinoma.

Publication types